Relapse pattern of GOG 122 trial should be more informative

dc.contributor.authorOzyar, Enis
dc.contributor.authorGenc, Mine
dc.date.accessioned2020-03-26T17:04:11Z
dc.date.available2020-03-26T17:04:11Z
dc.date.issued2006
dc.departmentSelçuk Üniversitesien_US
dc.description.abstract[Abstract not Available]en_US
dc.identifier.doi10.1200/JCO.2006.06.8833en_US
dc.identifier.endpage3710en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.issue22en_US
dc.identifier.pmid16877741en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3709en_US
dc.identifier.urihttps://dx.doi.org/10.1200/JCO.2006.06.8833
dc.identifier.urihttps://hdl.handle.net/20.500.12395/20647
dc.identifier.volume24en_US
dc.identifier.wosWOS:000239443400033en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAMER SOC CLINICAL ONCOLOGYen_US
dc.relation.ispartofJOURNAL OF CLINICAL ONCOLOGYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleRelapse pattern of GOG 122 trial should be more informativeen_US
dc.typeLetteren_US

Dosyalar